Advertisement

Skin Cancer

Studies Suggest Bright Future for Combination Immunotherapy in Advanced Melanoma, but Questions Remain

Two studies presented at the 2016 ASCO Annual Meeting focused on the use of combination immunotherapy in the treatment of patients...

Breast Cancer

PHEREXA: Benefit for Second-Line Pertuzumab Questionable

In the second-line metastatic breast cancer setting, the addition of pertuzumab to trastuzumab/capecitabine did not...

Gynecologic Cancers

Benefit Strongly Suggested With Hormonal Maintenance in Low-Grade Serous Carcinoma

In patients with low-grade serous carcinoma, maintenance hormonal therapy reduced the risk of recurrence by 77%, compared with surveillance...


Advertisement

More Top Stories

Multiple Myeloma

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial

Bladder Cancer

Atezolizumab Promising in Cisplatin-Ineligible Metastatic Bladder Cancer

Atezolizumab (Tecentriq), an anti–programmed cell death ligand 1 (PD-L1) inhibitor, achieved durable responses as first-line treatment in cisplatin-ineligible patients with metastatic urothelial carcinoma in a primary analysis of a phase II trial. These data represent an unmet need, because...

Advertisement

Some Adolescent Survivors of Childhood Cancer May Benefit From More Comprehensive Mental Health Screening

Most adolescent survivors of childhood cancer have no reported psychological symptoms, but an analysis led by St. Jude Children's Research Hospital found that those who do often have multiple symptoms and distinct symptom profiles. The findings, published by Krull et al in the Journal of Clinical...

Lung Cancer

Charles M. Rudin, MD, PhD, on SCLC: Findings on Rovalpituzumab Tesirine

Issues in Oncology
Symptom Management

Clinical Trials Actively Recruiting Patients With Cardiotoxicity Resulting From Treatment

Observational

Study Title: Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors

Study Type: Observational

Study Sponsor and Collaborators: Memorial Sloan Kettering Cancer
Center

Purpose: To study whether strain ...

Breast Cancer

Greatest Benefit of Adjuvant Exemestane in Premenopausal Women at Higher Risk of Breast Cancer Recurrence

In an analysis of the SOFT and TEXT trials reported in the Journal of Clinical Oncology, Meredith M. Regan, ScD, of Dana-Farber Cancer Institute, and colleagues found that the greatest benefit of adjuvant exemestane in reducing breast cancer recurrence was among women with the greatest risk of...

Ipilimumab Appears Active in Relapsed Hematologic Cancer After Allogeneic HSCT

In a phase I/Ib study reported in The New England Journal of Medicine, Davids et al found that ipilimumab (Yervoy; at a dose of 10 mg/kg) produced responses, including complete responses, in patients with relapsed hematologic cancer after allogeneic hematopoietic stem cell transplantation (HSCT)....

Bladder Cancer

Arjun Vasant Balar, MD, on Urothelial Carcinoma: Analysis of the IMvigor210 Cohort 1

Bladder Cancer

Atezolizumab Promising in Cisplatin-Ineligible Metastatic Bladder Cancer

Atezolizumab (Tecentriq), an anti–programmed cell death ligand 1 (PD-L1) inhibitor, achieved durable responses as first-line treatment in cisplatin-ineligible patients with metastatic urothelial carcinoma in a primary analysis of a phase II trial. These data represent an unmet need, because...

Advertisement

Study Finds New Whole-Exome Sequencing Test Accurately Identifies Actionable Mutations

Exome Cancer Test v1.0 (EXaCT-1), a new whole-exome sequencing test developed by the Englander Institute for Precision Medicine at Weill Cornell Medicine, detected mutations that guide precision cancer treatment with over 95% accuracy, according to a study by Rennert et al published in Genomic ...